Companion Diagnostic Collaboration and Licensing Deals 2016-2023

$3,995.00

Companion Diagnostic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023

Publication date
November 2023
Number of pages
150+
Product type
Research report
Available formats
PDF document
Report edition
4
SKU
CP2106

Companion Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of companion diagnostic deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 181 companion diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of companion diagnostic dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2016.

Chapter 3 provides an overview of the leading companion diagnostic deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostic dealmaking with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of companion diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific companion diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in companion diagnostic deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse companion diagnostic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Companion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Companion Diagnostic Collaboration and Licensing Deals includes:
•    Trends in companion diagnostic dealmaking in the biopharma industry
•    Directory of companion diagnostic deal records covering pharmaceutical and biotechnology
•    The leading companion diagnostic deals by value
•    Most active companion diagnostic licensing dealmakers

Companion Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse companion diagnostic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in companion diagnostic dealmaking
2.1. Introduction
2.2. Companion diagnostic deals over the years
2.3. Most active companion diagnostic dealmakers
2.4. Companion diagnostic deals by deal type
2.5. Companion diagnostic deals by therapy area
2.6. Companion diagnostic deals by industry sector
2.7. Deal terms for companion diagnostic deals
2.7.1 Companion diagnostic deals headline values
2.7.2 Companion diagnostic deal upfront payments
2.7.3 Companion diagnostic deal milestone payments
2.7.4 Companion diagnostic royalty rates

Chapter 3 – Leading companion diagnostic deals
3.1. Introduction
3.2. Top companion diagnostic deals by value

Chapter 4 – Most active companion diagnostic dealmakers
4.1. Introduction
4.2. Most active companion diagnostic dealmakers
4.3. Most active companion diagnostic deals company profiles

Chapter 5 – Companion diagnostic contracts dealmaking directory
5.1. Introduction
5.2. Companion diagnostic contracts dealmaking directory

Chapter 6 – Companion diagnostic dealmaking by technology type

Deal directory

Deal directory – Companion diagnostic deals by company A-Z
Deal directory – Companion diagnostic deals by deal type
Deal directory – Companion diagnostic deals by therapy area

Deal type definitions

About Wildwood Ventures    
Current Partnering
Current Agreements
Recent report titles from Current Partnering



Table of figures

Figure 1: Companion diagnostic deals since 2016
Figure 2: Active companion diagnostic dealmaking activity – 2016 - 2023
Figure 3: Companion diagnostic deals by deal type since 2016
Figure 4: Companion diagnostic deals by therapy area since 2016
Figure 5: Companion diagnostic deals by industry sector since 2016
Figure 6: Companion diagnostic deals with a headline value
Figure 7: Companion diagnostic deals with an upfront value
Figure 8: Companion diagnostic deals with a milestone value
Figure 9: Companion diagnostic deals with a royalty rate value
Figure 10: Top companion diagnostic deals by value since 2016
Figure 11: Most active companion diagnostic dealmakers 2016 - 2023
Figure 12: Companion diagnostic deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2cureX, A2 Biotherapeutics, Abbott Laboratories, Abbvie, Abcam, ADC Therapeutics, Adial Pharmaceuticals, Advanced Cell Diagnostics, Advanced Nuclear Medicine Ingredients, Agilent Technologies, Agios Pharmaceuticals, Akoya Biosciences, Allarity Therapeutics, Almac Diagnostics, Alphageneron Pharmaceuticals, Amgen, Amoy Diagnostics, Analytics Engines, AnHeart Therapeutics, ArcherDX, Arizona State University, Arvinas, Ashvattha Therapeutics, Astellas Pharma, AstraZeneca, Asuragen, Atlas Antibodies, AVEO Oncology, Bayer, Becton Dickinson, BeiGene, Biocartis, Biocept, Biodesix, BioMarker Strategies, Biomedix, BioNTech, BioSkryb, Bliss Biopharmaceutical, Blueprint Medicines, Boehringer Ingelheim, Bpifrance, Brenus Pharma, Bristol-Myers Squibb, Bristol-Myers Squibb Pakistan, Burning Rock, Calviri, CANbridge Pharmaceuticals, Caris Life Sciences, Celgene, Chembio Diagnostics, Chugai Pharmaceutical, Clovis Oncology, Companion Medical, Covance, Daiichi Sankyo, Day One Biopharmaceuticals, Debiopharm, Definiens, Denovo Biopharma, DiamiR, Dimerix Biosciences, Eisai, Eli Lilly, Enterome Bioscience, Epizyme, Erasmus University Medical Center, Eureka Eurostars, Eurofins Scientific, Exosome Diagnostics, FivepHusion, Five Prime Therapeutics, Flare Therapeutics, Foundation Medicine, Freenome, Fujirebio Diagnostics, Fusion Antibodies, FYR Diagnostics, Gemini Therapeutics, Genosity, German Federal Ministry of Education and Research, Gibson Oncology, Grail, GSK, Guardant Health, Helix, Hengrui Therapeutics, Henlius Biotech, HiberCell, Horizon Europe, HotSpot Therapeutics, HTG Molecular Diagnostics, IDbyDNA, Illumina, Imanis Life Sciences, IMIDomics, ImmunID Technologies, IMPACT Therapeutics, Incyte, Informed Data Systems, Inotrem, InSphero, Intezyne, InVivoScribe, Janssen Biotech, Janssen Research & Development, Johnson & Johnson Innovation, Kanazawa University, Kartos Therapeutics, Karyopharm Therapeutics, Kiyatec, Kronos Bio, Laboratory Corporation of America, Lantern Pharma, Leap Therapeutics, Leica Biosystems, Les Laboratoires Servier, Locus Biosciences, Loxo Oncology, MapKure, Massachusetts General Hospital, Mayo Clinic, Medicover, Medivation, Medx, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merrimack Pharmaceuticals, Mirati Therapeutics, Morphotek, Multimmune, Myriad Genetics, NanoString Technologies, Natera, National Cancer Institute, National Heart, Lung and Blood Institute, National Institutes of Health, Navigate BioPharma Services, NeuroMetrix, Neuron23, NMI TT Pharmaservices, North Carolina State University, Novartis, Novogene, Nucleai, NuSirt, Oncoheroes Biosciences, Oncology Venture, OncXerna Therapeutics, One Way Liver Genomics (OWL), OrigiMed, OSE Immunotherapeutics, PathAI, Personalis, Pfizer, Pierre Fabre, Pionyr Immunotherapeutics, Precision for Medicine, Profusa, Promega, Prometheus Biosciences, Proteomics International, Puma Biotechnology, Q BioMed, QED Therapeutics, Qiagen, R-Biopharm, R-Pharm, Race Oncology, Radius Health, Relay Therapeutics, Resolution Bioscience, Roche, Roche Diagnostics, Roche Molecular Systems, Scandion Oncology, Sengenics, Sentinel Oncology, Shenzhen Chipscreen Biosciences, Shuwen Biotech, Singulex, Skysong Innovations, Spectrum Pharmaceuticals, SRL, St. Jude Children's Research Hospital, Stanford University, Strata Oncology, STRATIFYER Molecular Pathology, Sysmex, T-Cure Bioscience, Takeda Pharmaceutical, Tasly Pharmaceuticals, Telix Pharmaceuticals, Tempus, Thermo Fisher Scientific, TP Therapeutics, TScan Therapeutics, uBiome, Unilabs, University of Arkansas, University of Bonn, University of Newcastle, University of Washington, Ventana Medical Systems, Vertex Pharmaceuticals, Viewpoint Molecular Targeting, Vyriad, WAVE Life Sciences, WuXi NextCODE Genomics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.